BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 25, 2011
 |  BC Week In Review  |  Company News  |  Deals

Hemispherx, Quest Pharma deal

Quest and Hemispherx partnered to evaluate Quest's cancer candidate oregovomab with Hemispherx's Ampligen rintatolimod to treat advanced ovarian cancer in a Phase I/II trial. The partners will equally split the $1 million...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >